Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes
MPR,
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion.
Even during a pandemic, the AHA says, research on obesity, hypertension, diabetes, and more continues to pay dividends.
American Heart Association While COVID-19 vaccines and variants continued to capture health headlines, a number of significant…
Efpeglenatide lowered the risk of cardiovascular and renal events in patients with type 2 diabetes who have a history of…
Weekly subcutaneous injections of efpeglenatide 4 mg or 6 mg were found to be associated with a decreased risk of…
Diabete Meno eventi cardiovascolari in alcuni pazienti con diabete di tipo 2 con efpeglenatide.
Weekly subcutaneous injections of efpeglenatide 4 mg or 6 mg were found to be associated with a decreased risk of…
Zu den zugelassenen, kurz- und langwirksamen GLP-1-Rezeptoragonisten (Inkretin-Mimetika) gehören Exenatid, Liraglutid…
Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.
13 名の先生が役に立ったと考えています。 2型糖尿病治療に用いられるGLP-1受容体作動薬には、心血管や腎への保護作用が期待されており、複数の臨床試験が進行中である。カナダ・McMaster UniversityのHertzel C.
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
HealthDay News — For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk…
Efpeglenatide, an investigational nonhuman exendin-based GLP-1 receptor agonist, may reduce the risk for cardiovascular and…
HealthDay News — For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk…
Un essai de phase 3 à grande échelle montre une réduction significative du risque de maladies cardiovasculaires et rénales Premiè…
The AMPLITUDE-O phase 3 trial showed that investigational drug efpeglenatide (Sanofi/Hanmi Pharmaceutical) – an exendin-based…
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease TUESDAY, June 29…
(HealthDay)—For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk for…
TUESDAY, June 29, 2021 -- For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease…
TUESDAY, June 29, 2021 (HealthDay News) -- For patients with type 2 diabetes and a history of cardiovascular disease or current…
medwireNews: Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk…
The AMPLITUDE-O phase 3 trial showed that investigational drug efpeglenatide (Sanofi/Hanmi Pharmaceutical) — an exendin-based…
Efpeglenatide, a long-acting exendin-4 based glucagon-like peptide-1 receptor agonist, offered significant benefits in…
Meeting Coverage > ADA Exendin-4-based drug succeeded in cardiovascular outcomes trial An investigational glucagon-like peptide-1…